NCT03447470View on ClinicalTrials.gov

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

September 29, 2023

Study Completion Date

September 29, 2023

Conditions
CancerSolid Tumor
Interventions
DRUG

RXC004

RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

DRUG

Nivolumab

"RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.~Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1"

Trial Locations (5)

SM2 5PT

Royal Marsden Hospital, Institute of Cancer Research, Sutton

SE1 9RT

Guys Hospital, London

M20 4BX

The Christie NHS Foundation Trust, Manchester

NE77DN

Sir Bobby Robson Cancer Trials Research Centre, Newcastle

OX3 7LE

Department of Oncology, Oxford

All Listed Sponsors
lead

Redx Pharma Ltd

INDUSTRY

NCT03447470 - Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies | Biotech Hunter | Biotech Hunter